Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Dividend --> Earnings--> M&A Announcement
One thing is for sure, JT and the BOD/Executive Committee has stated that the company is undervalued. Clearly the market disagrees, or at least has the forces that disagree outnumber the forces that agree. Since the CEO/BOD's actions are not causeing the market to increase the shareprice to levels that they consider properly valued, one way they can return value to the shareholders is through dividends. Ultimately, if they have the cash on hand and the expected performance that in their opinion warrants a higher share price, and yet it's not happening, then disseminating that value through dividends in lieu of share price is the least they can do. And as we agree, that would most likely provide some control over the market.
Share
New Message
Please login to post a reply